Emerging and Exploratory Biomarkers
Overview of APRI, NAFLD Fibrosis Score (NFS), automated Elecsys PRO-C3 (ADAPT), OWLiver (MASEF), LIVERFASt, and upgraded NIS2+ (NASHnext).
You may see older scores like APRI and NFS on online calculators, or newer specialized blood tests like automated Elecsys PRO-C3 (ADAPT), OWLiver (MASEF), LIVERFASt, and upgraded 2-marker NIS2+ (NASHnext) in specialty liver clinics and clinical trials. Note that commercial NASHnext at Labcorp has transitioned from the older 4-marker NIS4 panel to NIS2+ (miR-34a-5p + YKL-40, corrected for sex), removing HbA1c so changes in diabetes blood sugar no longer skew your liver score.
| Biomarker / Diagnostic | Type | Potential Use | Limitations |
|---|---|---|---|
| APRI | Serum-based fibrosis score based on AST and platelet count1 | Simple screening tool to determine risk of advanced fibrosis (≥F3); alternative to FIB-41 | Lower accuracy in MASLD compared with other diseases1 |
| NFS | Composite score (age, BMI, AST, ALT, albumin, platelets, diabetes status)1 | Simple screening tool to determine risk of advanced fibrosis (≥F3); alternative to FIB-41 | Performance varies across populations (ie, BMI ranges)1 |
| PRO-C3 (Elecsys® / ADAPT) | Direct type III collagen formation neo-epitope; automated Roche Elecsys® PRO-C3 immunoassay launched 20252,3 | Combined with platelet count, age, and diabetes status in the ADAPT score to stage advanced liver fibrosis (≥F3) and active fibrogenesis3 | Circulating PRO-C3 can also rise in extrahepatic fibrotic or solid-tumor desmoplastic processes4 |
| OWLiver®a | Lipidomics-based blood test5 | Provides up to 2 readouts: (1) classification of at-risk MASH (NAS ≥4 and ≥F2 using the MASEF score); (2) if not at-risk MASH, then likelihood of MASH vs isolated steatosis5 | Requires validation in larger cohorts, with simplified methodology and cost-effectiveness data before broad clinical adoption2,5 |
| LIVERFASt™a | Multi-marker panel (A2M, haptoglobin, apolipoprotein A1, total bilirubin, GGT, ALT, AST, fasting glucose, triglycerides, cholesterol), age, sex, and BMI6 | Noninvasive fibrosis and steatosis assessment6 | AI algorithm of biological parameters and limited evidence that characterize test performance at prespecified thresholds7,8 |
| NIS2+® (NASHnext®)a Upgrades legacy 4-marker NIS4™ |
2-biomarker serum score combining circulating miR-34a-5p and YKL-40 with sex correction (removes A2M and whole-blood HbA1c from legacy NIS4)9,10 | Identifies at-risk MASH (NAS ≥4 and F ≥2): <0.46 rules out at-risk MASH; ≥0.68 rules in at-risk MASH without glycemic HbA1c confounding (Labcorp 504960 / CPT 0468U)9,11 | Proprietary algorithm;11 optimized to detect active at-risk MASH rather than stage F4 cirrhosis in isolation9,10 |